New app aims to ease pancreatic cancer treatment journey

NCT ID NCT07047807

Recruiting now Symptom relief Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times

Summary

This study is testing a smartphone app called PDAC-PATHWAYS designed to provide information and support to people with pancreatic cancer who are about to start neoadjuvant therapy (treatment before surgery). The app includes educational modules and tools to help patients cope. Researchers want to see if it's practical and acceptable to use, enrolling 50 patients from one hospital.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: digital informational and supportive care app
What this could lead to: If successful, this app could provide a practical way to help pancreatic cancer patients better manage their treatment journey.
What could go wrong: This is a small, early feasibility study with only 50 participants. The app may not improve outcomes or be widely adopted.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PDAC - PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PDAC - PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Locations

Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.